Subscribe To
NPCE / NeuroPace, Inc. (NPCE) CEO Michael Favet on Q1 2023 Results - Earnings Call Transcript
NPCE News
By GlobeNewsWire
October 16, 2023
NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
MOUNTAIN VIEW, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transfor more_horizontal
By Seeking Alpha
September 5, 2023
NeuroPace: A Speculative Epilepsy Play
NeuroPace aims to improve the lives of epilepsy patients with its remote monitoring system. The company's RNS system offers personalized and real-time more_horizontal
By Seeking Alpha
August 11, 2023
NeuroPace, Inc. (NPCE) Q2 2023 Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Irina Ridley - Chief Legal Officer and more_horizontal
By Seeking Alpha
May 7, 2023
NeuroPace, Inc. (NPCE) CEO Michael Favet on Q1 2023 Results - Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Trip Taylor - Gilmartin Group Michael Fave more_horizontal
By GlobeNewsWire
April 3, 2023
NeuroPace to Present at the 22nd Annual Needham Virtual Healthcare Conference
MOUNTAIN VIEW, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transfo more_horizontal
By Seeking Alpha
March 2, 2023
NeuroPace, Inc. (NPCE) Q4 2022 Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE ) Q4 2022 Results Conference Call March 2, 2023 4:30 PM ET Company Participants Trip Taylor - Gilmartin Group Michael Fav more_horizontal
By GlobeNewsWire
December 21, 2022
NeuroPace to Present at the 41st Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transfor more_horizontal
By 24/7 Wall Street
November 23, 2022
Accelmed Partners Takes Activist Position in NPCE / Neuropace After Q3 Results
Fintel reports that Accelmed Partners II L.P. more_horizontal